TOPLINE:
New information supply no assistance for an increased danger for pancreatic cancer with usage of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for approximately 7 years, although longer-term information are required, scientists stated.
METHOD:
- Some research studies have actually raised issue about a possible increased danger for pancreatitis and pancreatic cancer in clients taking a GLP-1 RA.
- Detectives behind this population-based associate research study evaluated the association of GLP-1 RA treatment with pancreatic cancer occurrence over an average of 7 years in 543,595 grownups (imply age, 59.9 years; 51% females) with type 2 diabetes
- Treatment with basal insulin was utilized as an active comparator.
- The analyses represented significant confounding aspects and time-related predispositions and changed for treatment with other glucose-lowering medications and a history of pancreatitis.
TAKEAWAY:
- Throughout the research study duration, 33,377 clients (6.1%) utilized GLP-1 RAs and 106,849 (19.7%) utilized basal insulin, with 1665 of all clients identified with pancreatic cancer.
- There was no proof that GLP-1 RA usage increased pancreatic cancer threat compared to basal insulin.
- The approximated danger ratio (HR) for pancreatic cancer related to incremental usage of one specified daily dosage daily of GLP-1 RA compared to basal insulin in years 5-7 was 0.50 (95% CI, 0.15-1.71).
- New-user and widespread new-user analyses revealed HRs from year 5 onward following initiation of a GLP-1 RA vs basal insulin was 0.52 (95% CI, 0.19-1.41) and 0.75 (95% CI, 0.37-1.53), respectively.
IN PRACTICE:
Utilizing a number of analytical methods, these findings do not recommend a boost in pancreatic cancer occurrence over 7 years following the start of GLP-1 RA treatment, according to the examination. “However, keeping track of for pancreatic cancer danger beyond 7 years following initiation of treatment is still needed,” the authors composed.
SOURCE:
The research study, with very first author Rachel Dankner, MD, MPH, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Israel, was released online on January 4, 2024, in JAMA Network Open
CONSTRAINTS:
Information on the specific kind of GLP-1 RA were not offered. The analyses represented history of pancreatitis however not alcohol usage or direct exposure to pesticides/chemicals. Since of the threat for predisposition due to reverse causation, a focus was put on drug results numerous years after their initiation. This lowered the number of pancreatic cancer cases offered and led to approximated HRs with larger CIs.
DISCLOSURES:
The research study got no particular financing. The authors revealed no pertinent disputes of interest.